Rufinamide 400 mg/1 (Rufinamide TABLET, FILM COATED) 400 mg/1

Rufinamide 400 mg tablets are an anticonvulsant medication used to manage seizures. This film-coated tablet is manufactured by Mylan Pharmaceuticals Inc. and is available in a 120-count bottle.

Strength

400 mg/1

Pack Size

120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-2331-78)

Manufacturer / TM Owner

Mylan Pharmaceuticals Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Rufinamide is primarily used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome, a severe form of epilepsy. It works by stabilizing the electrical activity in the brain, helping to reduce the frequency and severity of seizures. Rufinamide 400 mg tablets are designed for oral administration and are intended for use under medical supervision.

Side Effects

Common effects of rufinamide may include dizziness, fatigue, and headache. Some users may also experience nausea or vomiting. These effects can vary from person to person and may subside as the body adjusts to the medication.

Precautions & Warnings

Rufinamide should be handled with care, stored in a cool, dry place, and kept out of reach of children. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Do not crush or chew the film-coated tablets.

Avoid Interactions

Rufinamide may interact with other medications, including those that affect liver enzymes. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain CYP inhibitors may also affect the efficacy of rufinamide.

Frequently Asked Questions

Rufinamide is used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome, a severe form of epilepsy.

Rufinamide 400 mg tablets are designed for oral administration. Follow the dosage and administration instructions provided by your healthcare professional.

Common side effects of rufinamide may include dizziness, fatigue, headache, nausea, and vomiting.

Rufinamide may interact with other medications, especially those that affect liver enzymes. Consult your healthcare provider before combining rufinamide with other drugs.

Rufinamide should be stored in a cool, dry place, away from heat and moisture, and out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.